GTBP · GT Biopharma, Inc. · Documents

Dec 23

Registration statement S-1

Registration statement

Nov 27

Current report 8-K Events of Nov 21

Delisting notice or listing transfer

Nov 21

Current report 8-K Events of Nov 18

Entered into a material agreement

Nov 14

Quarterly report 10-Q FY2024 Q3, ended Sep 30

Quarterly report for FY2024 Q3

Net loss $3.41M Diluted EPS -$1.53

Sep 16

Current report 8-K

Director or officer change, or executive pay

Aug 14

Quarterly report 10-Q FY2024 Q2, ended Jun 30

Quarterly report for FY2024 Q2

Net loss $3.71M Diluted EPS -$2.17

Jun 27

Current report 8-K

Other events

Jun 27

Registration statement S-1/A

Registration statement

Jun 26

Current report 8-K Events of Jun 25

Shareholder vote results

Jun 20

Registration statement S-1

Registration statement

Jun 17

Proxy statement DEFA14A

Proxy statement

Jun 7

Current report 8-K Events of Jun 3

Director or officer change, or executive pay

May 23

Current report 8-K Events of May 21

Entered into a material agreement, Unregistered sale of equity

May 15

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Net loss $2.27M Diluted EPS -$1.64

Apr 30

Current report 8-K Events of Apr 25

Entered into a material agreement

Apr 29

Proxy statement DEF 14A

Proxy statement

Apr 29

Annual report to holders ARS

Annual report to holders

Apr 29

Proxy statement DEFA14A

Proxy statement

Mar 26

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Net loss $7.6M Diluted EPS -$5.64

Feb 1

Current report 8-K

Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change, Regulation FD disclosure

Dec 21

Current report 8-K Events of Dec 18

Shareholder vote results

Dec 4

Current report 8-K

Other events

Nov 6

Proxy statement DEF 14A

Proxy statement

Nov 6

Proxy statement DEFA14A

Proxy statement

Nov 6

Proxy statement DEFA14A

Proxy statement

Nov 1

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Net loss $2.42M Diluted EPS -$0.06

Oct 27

Proxy statement PRE 14A

Proxy statement

Aug 22

Current report 8-K

Delisting notice or listing transfer

Aug 7

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Net loss $1.99M Diluted EPS -$0.05

Jul 5

Current report 8-K Events of Jun 28

Shareholder vote results

May 15

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Net loss $227K

May 5

Proxy statement DEFA14A

Proxy statement

May 5

Proxy statement DEFR14A

Proxy statement

May 4

Current report 8-K Events of May 1

Director or officer change, or executive pay

May 1

Proxy statement DEF 14A

Proxy statement

Mar 30

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Net loss $20.88M

Feb 28

Current report 8-K Events of Feb 22

Delisting notice or listing transfer

Jan 4

Current report 8-K Events of Dec 30

Entered into a material agreement, Other events

Dec 13

Current report 8-K Events of Dec 8

Director or officer change, or executive pay

Nov 9

Current report 8-K Events of Nov 3

Charter or bylaw amendment, or fiscal year change

Oct 31

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Net loss $6.88M

Oct 13

Registration statement S-3

Registration statement

Oct 12

Current report 8-K Events of Oct 10

Shareholder vote results

Oct 4

Current report 8-K

Other events

Oct 4

Proxy statement DEFA14A

Proxy statement

Aug 30

Current report 8-K Events of Aug 24

Entered into a material agreement

Aug 17

Proxy statement DEF 14A

Proxy statement

Aug 17

Current report 8-K/A Events of Jun 8

Shareholder vote results

Aug 15

Quarterly report 10-Q FY2022 Q2, ended Jun 30

Quarterly report for FY2022 Q2

Net loss $2.98M

Jun 14

Current report 8-K Events of Jun 8

Shareholder vote results